PARP1 EXPRESSION IS A STRONG PROGNOSTIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANT.

被引：0
|
作者：
Thomas, M. [1 ]
King, K. [2 ]
Seligson, N. [2 ]
机构：
[1] Univ Florida, Orlando, FL USA
[2] Univ Florida, Jacksonville, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-179
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [1] PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant
    Thomas, Melissa
    Li, Junan
    King, Kevan
    Persaud, Avinash K.
    Duah, Ernest
    Vangundy, Zachary
    Hofmeister, Craig C.
    Lamba, Jatinder K.
    Tan, Aik Choon
    Fridley, Brooke L.
    Poi, Ming J.
    Seligson, Nathan D.
    HAEMATOLOGICA, 2023, 108 (08) : 2155 - 2166
  • [2] Outcomes associated with advancing age in patients with multiple myeloma (MM) receiving stem cell transplant.
    Beveridge, C. A.
    Ershler, W. B.
    Orloff, G. J.
    Sheridan, M. J.
    Shelton, M. V.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (04) : S55 - S56
  • [3] PHARMACOKINETICS AND PHARMACODYNAMICS OF HIGH DOSE MELPHALAN IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT.
    Cho, Y.
    Wang, J.
    Gao, Y.
    Li, J.
    Lamprecht, M.
    Jukich, M.
    Schaaf, L. J.
    Poi, M.
    Hofmeister, C. C.
    Phelps, M. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S38 - S38
  • [4] Prognostic significance of cytogenetics in patients with multiple myeloma referred for autologous stem cell transplant (ABMT).
    Simpson, DR
    Berkahn, LC
    Squire, J
    Meharchand, J
    Dube, ID
    Sutton, DM
    Crump, RM
    Keating, A
    Stewart, AK
    BLOOD, 1997, 90 (10) : 2349 - 2349
  • [5] Prognostic relevance of CD56 expression in patients with multiple myeloma treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
    Yeung, J
    Samiee, S
    Yi, QL
    Pantalony, D
    Chang, H
    BLOOD, 2005, 106 (11) : 353B - 353B
  • [6] Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma
    Dunavin, Neil C.
    Wei, Lai
    Elder, Patrick
    Phillips, Gary S.
    Benson, Don M., Jr.
    Hofmeister, Craig C.
    Penza, Sam
    Eld, Carli Greenfi
    Rose, Karen S.
    Rieser, Gisele
    Merritt, Lisa
    Ketcham, Jill
    Heerema, Nyla
    Byrd, John C.
    Devine, Steven M.
    Efebera, Yvonne A.
    LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1658 - 1664
  • [7] Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma
    Dunavin, Neil
    Habib, Joyce
    Phillips, Gary
    Elder, Patrick
    Tranovich, Meaghan
    Benson, Don M., Jr.
    Hofmeister, Craig C.
    Byrd, John C.
    Devine, Steven M.
    Efebera, Yvonne
    BLOOD, 2010, 116 (21) : 1466 - 1467
  • [8] An Iterative Formative Evaluation of Medical Education for Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant
    Halpin, Sean N.
    Konomos, Michael
    JOURNAL OF CANCER EDUCATION, 2022, 37 (03) : 779 - 787
  • [9] An Iterative Formative Evaluation of Medical Education for Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant
    Sean N. Halpin
    Michael Konomos
    Journal of Cancer Education, 2022, 37 : 779 - 787
  • [10] Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma
    Halpin, Sean N.
    Konomos, Michael
    Jowers, Ivey
    JOURNAL OF PATIENT EXPERIENCE, 2021, 8
12345